Breast cancer in premenopausal women: Recurrence and survival rates and relationship to hormone replacement therapy

Climacteric

Volumn 7, Issue 3, 2004, Pages 284-291

  Durna, E M ^a   Heller, G Z ^b   Leader, L R ^a   Sjoblom, P ^a   Eden, J A ^a,c   Wren, B G ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c ROYAL HOSPITAL FOR WOMEN   (Australia)

Author keywords

Breast cancer; Estrogen plus progestin; Hormone replacement therapy; Menopause

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL VALERATE; ESTRIOL; ESTROGEN; ESTRONE SULFATE; GESTAGEN;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; OUTCOMES RESEARCH; PREMENOPAUSE; PRIORITY JOURNAL; SURVIVAL RATE; SYMPTOMATOLOGY;

ADULT; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEW SOUTH WALES; PREMENOPAUSE; PROGESTINS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 4944252328     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/13697130400001380     Document Type: Article

References (27)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33
2. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27
3. Roy JA, Sawka CA, Pritchard KI. Hormone replacement therapy in women with breast cancer: do the risks outweigh the benefits? J Clin Oncol 1996;14:997-1006
4. Rostom AY. The management of menopausal sequelae in patients with breast cancer. Clin Oncol 2001;13:174-80
5. Beckman MW, Jap D, Djahansouzi S, et al. Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates. Oncology 2001;60:199-206
6. Eden JA, Bush T, Nand S, et al. A case-control study of combined continuous estrogen-progestin replacement therapy among women with personal history of breast cancer. Menopause 1995;2:67-72
7. Eden JA, Wren BG. Hormone replacement therapy after breast cancer: a review. Cancer Treat Rev 1996;22:335-43
8. Dew J, Eden J, Beller E, et al. A cohort study of hormone replacement therapy given to women previously treated for breast cancer. Climacteric 1998;1:137-42
9. Marsden J, Baum M, Sacks NPM. Hormone replacement therapy in women with previous breast cancer. Trends Endocrinol Metab 1998;9:32-8
10. Vassilopolou-Sellin R, Asmar L, Hortobagyi GN, et al. Estrogen replacement therapy after localised breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 1999;17:1482-7
11. Natrajan PK, Soumakis K, Gambrell RD. Estrogen replacement therapy in women with previous breast cancer. Am J Obstet Gynecol 1999;181:288-95
12. Natrajan PK, Puthugramam K, Gambrell RD. Estrogen replacement therapy in patients with early breast cancer. Am J Obstet Gynecol 2002;187:289-95
13. Uršis-Vrščaj M, Bebar S. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 1999;25:146-51
14. O'Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001;93:754-62
15. Col NF, Hirota LK, Orr RK, et al. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol 2001;19:2357-63
16. Peters GN, Fodera T, Sabol J, et al. Estrogen replacement therapy after breast cancer: a 12-year follow-up. Ann Surg Oncol 2001;8:828-32
17. Durna EM, Wren BG, Heller GZ, et al. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med J Aust 2002;177:347-51
18. De La Rochefordiere A, Asselain B, Campana F, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet 1993;341:1039-43
19. Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormonal replacement therapy in menopausal women: endometrial hypoplasia and irregular bleeding. Cochrane Database Syst Rev 2000;2:CD000402
20. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flushes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-63
21. Norman SG, Studd JW. A survey of views on hormone replacement therapy. Br J Obstet Gynaecol 1994;101:879-87
22. Dennerstein L, Shelley J, Smith AM, Ryan M. Hysterectomy experience among mid-aged Australian women. Med J Aust 1994;161:311-13
23. Lee CG, McCormick B, Mazumdar M, et al. Infiltrating breast carcinoma in patients age 30 years and younger: long term outcome for life, relapse and second primary tumors. Int J Radiat Oncol Biol Phys 1992;23:969-75
24. Durna EM, Crowe SM, Leader LR, et al. Quality of life of breast cancer survivors: the impact of hormonal replacement therapy. Climacteric 2002;5:266-76
25. Vassilopoulou-Selin R, Zolinski C. Estrogen replacement therapy in women with breast cancer: A survey of patient attitudes. Am J Med Sci 1992;304:145-9
26. Clayden JR, Bell JW, Pollard P. Menopausal flushing: double-blind trial of a non-hormonal medication. Br Med J 1974;1:409-12
27. Clemons M, Danson S, Howell A. Tamoxifen ('Nolvadex'): a review. Cancer Treat Rev 2002;28:165-80